Literature DB >> 16731012

Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure.

Mao Chen1, Zhong-Cai Fan, Xiao-Jing Liu, Jue-Lin Deng, Li Zhang, Li Rao, Qing Yang, De-Jia Huang.   

Abstract

To investigate whether stem cell transplantation affects ventricular electrophysiology in vivo, either autologous bone marrow mesenchymal stem cells or skeletal myoblast cells were transplanted via a catheter into a doxorubicin-treated failing heart. Four weeks after transplantation, electrophysiological investigation showed that transplantation of either cell type prolonged the local activation time and increased the activation time dispersion. In the stem cell transplantation groups, a positive correlation was demonstrated between activation time dispersion and the number of stem cell-derived cells in the pacing site. It is concluded that transplantation of either mesenchymal stem cells or skeletal myoblast cells might exacerbate abnormalities of local ventricular conduction in the doxorubicin-treated failing heart.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731012     DOI: 10.1016/j.cellbi.2006.03.002

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  12 in total

1.  Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy.

Authors:  Cyril Catelain; Stéphanie Riveron; Aurélie Papadopoulos; Nathalie Mougenot; Adeline Jacquet; Karine Vauchez; Erica Yada; Michel Pucéat; Marc Fiszman; Gillian Butler-Browne; Gisèle Bonne; Jean-Thomas Vilquin
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

Review 2.  Electrophysiological challenges of cell-based myocardial repair.

Authors:  Huei-Sheng Vincent Chen; Changsung Kim; Mark Mercola
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

3.  Stromal cell-derived factor-1 promotes bone marrow-derived cells differentiation to cardiomyocyte phenotypes in vitro.

Authors:  M Chen; H-Q Xie; L Deng; X-Q Li; Y Wang; W Zhi; Z-M Yang
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

Review 4.  Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears.

Authors:  Fernando Ezquer; Jaime Gutiérrez; Marcelo Ezquer; Christian Caglevic; Helio C Salgado; Sebastián D Calligaris
Journal:  Stem Cell Res Ther       Date:  2015-06-24       Impact factor: 6.832

5.  An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy.

Authors:  Jesús Talavera; Alejandro Giraldo; María Josefa Fernández-Del-Palacio; Obdulio García-Nicolás; Juan Seva; Gavin Brooks; Jose M Moraleda
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

6.  Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy.

Authors:  Danúbia Silva Dos Santos; Guilherme Visconde Brasil; Isalira Peroba Rezende Ramos; Fernanda Cristina Paccola Mesquita; Tais Hanae Kasai-Brunswick; Michelle Lopes Araújo Christie; Gustavo Monnerat Cahli; Raiana Andrade Quintanilha Barbosa; Sandro Torrentes da Cunha; Jonathas Xavier Pereira; Emiliano Medei; Antonio Carlos Campos de Carvalho; Adriana Bastos Carvalho; Regina Coeli Dos Santos Goldenberg
Journal:  Stem Cell Res Ther       Date:  2018-02-05       Impact factor: 6.832

7.  Proliferation-related changes in K+ content in human mesenchymal stem cells.

Authors:  Irina Marakhova; Alisa Domnina; Alla Shatrova; Aleksandra Borodkina; Elena Burova; Natalja Pugovkina; Victoria Zemelko; Nikolay Nikolsky
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

8.  Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure.

Authors:  Gregor Poglajen; Gregor Zemljič; Andraž Cerar; Sabina Frljak; Martina Jaklič; Vesna Androcec; Bojan Vrtovec
Journal:  Cell Transplant       Date:  2019-05-02       Impact factor: 4.064

9.  Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias.

Authors:  Sarah Fernandes; Harold V M van Rijen; Virginie Forest; Stéphane Evain; Anne-Laure Leblond; Jean Mérot; Flavien Charpentier; Jacques M T de Bakker; Patricia Lemarchand
Journal:  J Cell Mol Med       Date:  2009-03-06       Impact factor: 5.310

Review 10.  Potential and clinical utility of stem cells in cardiovascular disease.

Authors:  Korff Krause; Carsten Schneider; Kai Jaquet; Karl-Heinz Kuck
Journal:  Stem Cells Cloning       Date:  2010-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.